Astrazeneca PLC ORD SHS $0.25
Astrazeneca PLC ORD SHS $0.25/ GB0009895292 /
AZN
|
13/05/2024 09:33:34
|
Var.
+18.0000
|
Volume |
Denaro09:33:34 |
Lettera09:33:34 |
Capitalizzazione di mercato |
Dividend Y. |
Rapporto P/E |
|
12,388.0000GBX
|
+0.15%
|
87,245
Fatturato(GBP): 10.69 mill. |
12,388.0000Quantità in denaro: 112 |
12,392.0000Quantità in lettera: 161 |
192.32 bill.GBP |
- |
- |
Descrizione business
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Consiglio di amministrazione & Consiglio di sorveglianza
| CEO |
| Pascal Soriot |
| Consiglio di amministrazione |
| Aradhana Sarin, Pam Cheng, Ruud Dobber, Marc Dunoyer, David Fredrickson, Susan Galbraith, Menelas (Mene) Pangalos, Jeff Pott, Iskra Reic, Leon Wang, Sharon Barr |
| Consiglio di sorveglianza |
| Michel Demaré, Pascal Soriot, Aradhana Sarin, Philip Broadley, Euan Ashley, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, Marcus Wallenberg |
Dati aziendali
| Name: |
AstraZeneca plc |
| Indirizzo: |
1 Francis Crick Avenue Cambridge Biomedical Campus,Cambridge, CB2 0AA United Kingdom |
| Telefono: |
0800 783 0033 |
| Fax: |
+44-20-7604-8151 |
| E-mail: |
Medical.InformationU...eca.com
Medical.InformationUK@astrazeneca.com
|
| Internet: |
www.astrazeneca.com |
| Industria: |
Healthcare |
| Settore: |
Pharmaceutical Industry |
| Sub settore: |
Pharmaceuticals |
| Fine dell'anno finanziario: |
31/12 |
| Flottante libero: |
- |
| Data dell'IPO: |
06/04/1999 |
Company calendar
|
CW 30 | 25/07/2024
Interim Report 2nd Quarter/6 Months
|
|
CW 32 | 08/08/2024
Ex-Dividend
|
|
CW 32 | 09/08/2024
Record Date
|
|
CW 37 | 09/09/2024
Dividend Payment
|
|
CW 46 | 12/11/2024
Interim Report 3rd Quarter/9 Months
|
